NASDAQ:TGTX News 3 November 2025 - 11 January 2026

New York, January 9, 2026, 15:59 (EST) — Regular session TG Therapeutics (TGTX.O) shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session. The move comes with the J.P. Morgan Healthcare Conference set to kick off on Monday in San Francisco, a meeting that often pulls in fresh corporate updates and deal chatter in one tight week. The bank’s agenda shows the event runs

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseasesgurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S.gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis (RMS)ir.tgtherapeutics.com. It